Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: RNA sequencing of EMT6 syngeneic mouse tumor tissue with and without drug over time

PROVIDER: PRJNA478198 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7441600_1.fastq.gz	Fastqsanger.gz
	SRR7441600_2.fastq.gz	Fastqsanger.gz
	SRR7441610_1.fastq.gz	Fastqsanger.gz
	SRR7441610_2.fastq.gz	Fastqsanger.gz
	SRR7441620_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 180

Similar Datasets

Project description:RNA sequencing of B16F0 syngeneic mouse tumor tissue with and without drug over time

| PRJNA478383 | ENA

Project description:RNA sequencing of MC38 mouse tumor tissue with and without drug over time

| PRJNA477557 | ENA

Project description:RNA sequencing of syngeneic mouse tumor tissue at baseline

| PRJNA478219 | ENA

Gene expression profiling using RNA-Seq data of 12 mouse syngeneic tumor models treated with lenvatinib

Project description:We performed RNA-Seq analysis using total RNA extracted from tumor tissues of 12 mouse syngeneic tumor models resected from mice orally administered lenvatinib (10 mg/kg once daily), without any treatment (No Treatment) for 7 days (Day 8 NT or Day 8 LEN), or tumor tissues resected from mice when tumor volume reached approximately 100 mm3 (Baseline NT), to investigate the baseline characteristics of 12 tumor models and differentially expressed genes by the drug treatment.

2025-01-22 | GSE281579 | GEO

Gene expression changes in mouse breast tumor tissue (EMT6) after anti-PD-L1 resistance

Project description:RNA sequencing analysis was used to identify changes in mouse breast tumor tissues (EMT6) resistant to anti-PD-L1 (PDR).

2024-10-14 | GSE186032 | GEO

RNA-seq tumor immunome analysis of murine breast cancer model EMT6-hHER2 responsive to novel antibody drug conjugate T-PNU

Project description:An orthotopic murine breast cancer model was created by transfecting the human HER2 gene into the breast cancer cell line EMT6 resulting in EMT6-hHER2. Previous in vivo tumor treatments with trastuzumab, trastuzumab-emtansine (T-DM1) and a novel antibody drug conjugate (ADC) T-PNU (provided by NBE therapeutics and carrying the highly potent anthracycline analogue PNU-159682) revealed that EMT6-hHER2 tumors are unresponsive to standard therapy treatments of trastuzumab and T-DM1, but respond well to the novel ADC T-PNU. Identifying immunogenic cell death properties of T-PNU, we postulated a therapeutic relevance for T-PNU mediated immune modulation of the tumor microenvironment. In order to identify the transcriptional pathways underlying the T-PNU anti-tumor response, we performed RNA-sequencing analysis of CD45+ tumor-derived cells from differently treated cohorts (untreated, trastuzumab, T-DM1, T-PNU; n=6).

2018-10-06 | GSE120888 | GEO

Bulk RNA-Seq analysis of CD8+ T cells from treatment-naïve matched tumor-bearing lungs and spleens from the HKP1 orthotopic mouse lung adenocarcinoma model

Project description:To investigate how gene expression profiles change in CD8+ T cells based on time, tumor burden, and tissue localization, we orthotopically implanted the mouse lung adenocarcinoma HKP1 cell line expressing luciferase into syngeneic C57BL/6 mice by tail vein injections. Tumor growth was monitored by bioluminescence imaging. A separate cohort of mice received no tumor implantation. At days 7, 17, and 24 post tumor implantation, mice were euthanized and CD8+ T cells sorted from tumor-bearing lungs and spleens, or matched naive lungs and spleens. We then performed gene expression profiling analysis using data obtained from RNA-seq of sorted cells, comparing across time, tumor burden, and tissue localization.

2023-10-19 | GSE218141 | GEO

Project description:RNA sequencing of MC38 mouse tumor tissue with escalating drug dose

| PRJNA477829 | ENA

DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and in response to immunotherapy [DNA barcodes: All_EMT6_BC5000]

Project description:To investigate immunoediting at the primary tumour, we used DNA barcoding combined with NGS. By stably integrating EMT6 murine cancer cell line with 5000 unique DNA barcodes (1 barcode per cell), we can trace how barcode (and therefore subclonal) diversity changes over time and after treatment with immunotherapy.

2022-08-02 | GSE210047 | GEO

Gene expression changes in mouse breast tumor tissue (EMT6) after anti-PD-L1 resistance

Project description:Gene expression changes in mouse breast tumor tissue (EMT6) after anti-PD-L1 resistance

| PRJNA772170 | ENA